• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

NEW DELHI: Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration, to manufacture and market Gabapentin tablets used to treat seizures.

The Ranbaxy formulations have the same therapeutic effect as that of the Pfizer's Neurontin, which has total sales of $2.2 billion. Mr Jim Meehan, Vice-President, Sales and Marketing, Ranbaxy Pharmaceuticals Inc, said: "We are pleased to receive this final approval for Gabapentin Tablets. We will now focus on maximising the value of this formulation, that will have a positive impact on our performance for the balance of this year."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ONGC secures insurance claim for BHN platform

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line